Harvard University

September ended and October began with an explosion of new venture capital available for biotech companies, raising expectations for VC fundraising by drug developers through the rest of 2024, especia

As the improvements made possible with artificial intelligence and machine learning for biopharmaceutical research and development become clear, deal making in the space has skyrocketed. S&P Global pr

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Boehringer Ingelheim GmbH is closely

London-based vaccine company Vicebio Ltd. has become the 17th company this year to raise a nine-figure series B round, according to Evaluate data. TCGX led its $100m series B venture capital round,